YOU WONT BELIEVE: Molly wen - What They Never Told You

New Drugs Approvals Bring No Relief for Ailing Innovent Bio

Key Takeaways: Innovent Bio has brought several drugs to market in recent years, including two announced last week, but is still losing money with no profits in sight The company has overhauled its commercialization model and is doing more licensing partnerships with multinationals to expand its drug pipeline By Molly…

Benzinga · Oct 18, 2022

Betters Medical Looks Ailing Going Into Hong Kong IPO

Key Takeaways: Betters Medical has launched a Hong Kong listing, relying on high-margin microwave ablation needles as its major revenue contributor The company could face liability of tens of millions of yuan for failing to meet terms of an agreement with one of the investors in its Series C funding…

Benzinga · Sep 22, 2022

Junshi Biosciences Hits Revenue Roadblock Amid Covid Drug Delay

Key Takeaways: The company logged a revenue fall of 55% in the first half of the year and posted a loss of $131 million Phase 3 clinical trials for its Covid-19 oral drug wrapped up in May but the company has still not yet filed an application to market the…

Benzinga · Sep 9, 2022

CStone Pharma Replaces Chairman Amid Huge Losses, Irregular Investment

Key Takeaways: CStone brought four products to market last year, and its losses have surged due to growing R&D and sales spending Appointment of chairman with close ties to WuXi AppTec reveals a power struggle between shareholders and management By Molly Wen

Benzinga · Jun 7, 2022

One-Trick Pony Boan Biotech Files for Hong Kong IPO Into Tough Market

Key Takeaways: Boan Biotechnology sells only one product so far and is facing stiff competition from other similar drugs Luye Pharma bought Boan in 2020 and is taking it public at a time when markets are bearish By Molly Wen

Benzinga · May 24, 2022

Shenzhen Edge Medical Seeks Place in China's Surgical Robot Market

Key takeaways: Shenzhen Edge Medical has applied for a Hong Kong IPO, following China’s approval for the sale of one of its key products in January Company will face challenges from a growing number of domestic rival products already on the market By Molly Wen

Benzinga · Apr 26, 2022

AI Pharma Startup METiS Raises $150 Million. IPO In Sight?

Key takeaways: METiS Pharmaceuticals has completed five funding rounds since its establishment in January 2020, including the latest two worth $150 million The company was incubated by AI pharmaceutical unicorn XtaiPl, whose most recent valuation exceeded $2.05 billion By Molly Wen

Benzinga · Apr 12, 2022

Dental Care Provider Arrail Hopes Investors Will Smile on Its Hong Kong IPO

Key takeaways Arrail Group has passed a listing hear in Hong Kong after becoming profitable at the operating level in its latest fiscal year Company hopes to take advantage of a fragmented Chinese dental market that could be worth 300 billion annually yuan by 2025 By Molly Wen

Benzinga · Mar 4, 2022

GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment

Key takeaways: GenScript Biotech said it lost up to $519 million last year, with its Legend Biotech unit accounting for nearly 70% of that Legend Biotech’s Cilta-cel CAR-T cell therapy product was approved by the FDA on Monday, and could become a major cash cow for GenScript Biotech By Molly…

Benzinga · Mar 1, 2022

Jiangsu Recbio Shoots To Become Hong Kong's First HPV Vaccine Stock

Key takeaways: Jiangsu Recbio has filed a second IPO application to list in Hong Kong, hoping to become the first HPV vaccine maker in the market The company was valued at around 9 billion yuan after its latest funding round By Molly Wen

Benzinga · Jan 27, 2022